Alvotech (ALVO) Expected to Announce Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to issue its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.0197) per share and revenue of $134.22 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Alvotech (NASDAQ:ALVO) last released its quarterly earnings results on Thursday, August 20th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The business had revenue of $106.00 million for the quarter, compared to analysts’ expectations of $103.00 million. On average, analysts expect Alvotech to post ($0.01) EPS for the current fiscal year and $0.22 EPS for the next fiscal year.

Alvotech Price Performance

Alvotech stock opened at $4.54 on Wednesday. The company’s 50-day moving average price is $5.30 and its two-hundred day moving average price is $4.22. Alvotech has a twelve month low of $2.94 and a twelve month high of $6.53.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Evercore started coverage on Alvotech in a research report on Friday, August 14th. They issued an “outperform” rating on the stock. UBS Group set a $8.00 target price on Alvotech in a research note on Wednesday, September 16th. Barclays raised Alvotech from an “underweight” rating to an “overweight” rating and lifted their price target for the stock from $4.00 to $8.00 in a report on Wednesday, September 16th. Weiss Ratings downgraded Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Finally, Zacks Research downgraded Alvotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Four investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Alvotech has a consensus rating of “Hold” and a consensus price target of $8.25.

Alvotech Company Profile

Alvotech is a biotechnology company headquartered in Reykjavík, Iceland, focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to already approved reference medicines and are intended to expand patient access to complex treatments at potentially lower costs.

The company uses an integrated research, development and manufacturing model and concentrates on therapeutic areas including immunology, ophthalmology, oncology and bone health.